AtriCure Inc (NAS:ATRC)
$ 22.81 -0.955 (-4.02%) Market Cap: 1.10 Bil Enterprise Value: 1.12 Bil PE Ratio: 0 PB Ratio: 2.42 GF Score: 72/100

AtriCure Inc To Host an Investor Education Webcast Transcript

Sep 28, 2022 / 06:00PM GMT
Release Date Price: $39.53 (+3.35%)
Angela L. Wirick
AtriCure, Inc. - CFO

(technical difficulty) Of Certain remarks that may include forward-looking statements, as we've noted in the accompanying slide.

In AtriCure's first investor education webcast, we are really excited to have 2 key opinion leaders for the Convergent Hybrid AF therapy with us today to share their experience with program development and expansion.

As many of you know, this therapy was launched last year following the PMA approval of the EPi-Sense system for treatment of patients with long-standing persistent Afib.

This approval resulted from the groundbreaking CONVERGE trial which demonstrated the superiority of Hybrid AF therapy using the EPi-Sense device to endocardio catheter ablation alone. The accompanying slide illustrates some of the key takeaways from the CONVERGE trial and notably, the durability and (inaudible) efficacy of the procedure while also providing significant burden reduction for long-standing persistent patients, and time savings for EPs with these difficult and complex cases.

We believe these results are

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot